

INRA/INSERM/AMU  
Fac Médecine La Timone  
13385 Marseille

[jean-charles.martin@univ-amu.fr](mailto:jean-charles.martin@univ-amu.fr)

## LA METABOLOMIQUE ET SES APPLICATIONS EN BIOLOGIE: POURQUOI, COMMENT, BUT ET PERSPECTIVES



**Le mot métabolisme provient du grec “μεταβολήσμος” (metabo-lismo), qui signifie “changement.”**



**Concept du metabolisme par Ibn al-Nafis (1213–1288):**

**« *Le corps et ses partis sont en état perpétuel de dissolution et de reconstitution, de sorte qu'ils subissent inévitablement un changement permanent* »**

# Quelques définitions.....

## Métabolite

Est une molécule organique <1500 Da détectable dans un organisme, incluant des molécules d'origine endogènes ou exogènes, issus des micro-organismes

## Le Métabolome

Est un terme utilisé pour la première fois par Olivier et al en 1998 pour décrire un **ensemble de métabolites** synthétisés par un organisme

## La Métabolomique

A été formulée par Oliver Fiehn et est définie par une **analyse complète non sélective** dans laquelle tous les métabolites d'un système biologique sont identifiés et quantifiés

## La Métabonomique

Est définie par la **mesure quantitative de la réponse métabolique** multiparamétrique des systèmes vivants à un stimuli ou une altération génétique (Jeremy Nicholson)

## Profilage des métabolites

Implique l'identification et la quantification d'un **ensemble ou d'une classe prédéfinis** de métabolites d'identités connus ou inconnus et appartenant à des voies métaboliques particulières.

*Le métabolome représente l'ultime réponse d'un organisme à une altération génétique, une pathologie, une exposition à un toxique ou toute cause environnementale. Le métabolome d'un système peut ainsi à la fois permettre de lire la signature biologique d'une réponse adaptative ou pathologique, et également être le vecteur de cette réponse. Ce dernier aspect souligne l'implication directe du métabolome dans le déterminisme des phénotypes*


# OPINION

## 2020 visions

For the first issue of the new decade, *Nature* asked a selection of leading researchers and policy-makers where their fields will be ten years from now. We invited them to identify the key questions their disciplines face, the major roadblocks and the pressing next steps. Visit [go.nature.com/htW8uM](http://go.nature.com/htW8uM) to respond and to add your vision.

Microbiome      Energy      Synthetic  
Perso      Metabolomics      \*  
medicine      Astronomy      palaeontology  
Drug discovery      Chemistry      Lasers

# Les petites molécules sont présentent dans tous les systèmes...



# Le Metabolome est Connecté à tous les autres “Omes”

- Small molecules (i.e. AMP, CMP, GMP, TMP) are the primary constituents of the genome & transcriptome
- Small molecules (i.e. the 20 amino acids) are the primary constituents of the proteome
- Small molecules (i.e. lipids) give cells their shape, form, integrity and structure
- Small molecules (sugars, lipids, AAs, ATP) are the source of all cellular energy
- Small molecules serve as cofactors and signaling molecules for both the proteome and the genome
- *The genome & proteome largely evolved to catalyze the chemistry of small molecules*

## Integrating metabolomics into systems biology framework to exploit metabolic complexity: strategies and applications in microorganisms

Appl Microbiol Biotechnol (2006) 70: 151–161  
DOI 10.1007/s00253-005-0277-2

Metabolomics tools for identifying biomarkers for neuropsychiatric diseases

Neurobiology of Disease 35 (2009) 165–176

Emerging high-throughput approaches to analyze bioremediation of sites contaminated with hazardous and/or recalcitrant wastes

Biotechnology Advances 26 (2008) 561–575

### High-Throughput Technique for Comprehensive Analysis of Japanese Green Tea Quality Assessment Using Ultra-performance Liquid Chromatography with Time-of-Flight Mass Spectrometry (UPLC/TOF MS)

J. Agric. Food Chem. 2008, 56, 10705–10708

## Metabolomics in monitoring kidney transplants

Wishart, David S

Current Opinion in Nephrology & Hypertension:  
November 2006 - Volume 15 - Issue 6 - p 637-642

## Metabonomics in pharmaceutical R & D

John C. Lindon, Elaine Holmes and Jeremy K. Nicholson

FEBS Journal 274 (2007) 1140–1151

Regulation of floral scent production in petunia revealed by targeted metabolomics  
Phytochemistry 62 (2003) 997–1008

## Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease

Zeneng Wang<sup>1,2</sup>, Elizabeth Klipfell<sup>1,2</sup>, Brian J. Bennett<sup>3</sup>, Robert Koeth<sup>1</sup>, Bruce S. Levison<sup>1,2</sup>, Brandon DuGar<sup>1</sup>, Ariel E. Feldstein<sup>1,2</sup>, Earl B. Britt<sup>1,2</sup>, Xiaoming Fu<sup>1,2</sup>, Yoon-Mi Chung<sup>1,2</sup>, Yuping Wu<sup>4</sup>, Phil Schauer<sup>5</sup>, Jonathan D. Smith<sup>1,6</sup>, Hooman Allayee<sup>7</sup>, W. H. Wilson Tang<sup>1,2,6</sup>, Joseph A. DiDonato<sup>1,2</sup>, Aldons J. Luisi<sup>3</sup> & Stanley L. Hazen<sup>1,2,6</sup>

Physiologia Plantarum 132: 162–175. 2008

## Plant metabolomics and its potential application for human nutrition

Robert D. Hall<sup>a,b,\*</sup>, Inge D. Brouwer<sup>c</sup> and Melissa A. Fitzgerald<sup>d</sup>

Metabolomics in human nutrition: opportunities and challenges

Am J Clin Nutr 2005;82:497–503

## Applications of Metabolomics in Agriculture

RICHARD A. DIXON,<sup>†</sup> DAVID R. GANG,<sup>‡</sup> ADRIAN J. CHARLTON,<sup>§</sup> OLIVER FIEHN,<sup>#</sup>  
HARRY A. KUIPER,<sup>||</sup> TRACEY L. REYNOLDS,<sup>¶</sup> RONALD S. TJEERDEMA,<sup>¤</sup>  
ELIZABETH H. JEFFERY,<sup>¤</sup> J. BRUCE GERMAN,<sup>¤</sup> WILLIAM P. RIDLEY,<sup>\*¶</sup> AND  
JAMES N. SEIBER<sup>¤</sup>

8984 J. Agric. Food Chem. 2006, 54, 8984–8994

Metabonomic modeling of drug toxicity


Hector C. Keun \*

Pharmacology & Therapeutics 109 (2006) 92 – 106


## Metabolomic Profiling for Identification of Novel Potential Biomarkers in Cardiovascular Diseases

Journal of Biomedicine and Biotechnology  
Volume 2011, Article ID 790132, 9 pages


## Comment j'en suis arrivé à la métabolomique... et autres omiques



# contexte pro-athérogène



les **stries lipidiques** (dépôts d'esters de cholestérol) **marqueurs circulants** (lipoprotéines, paraoxonase, apo SAA) **expression gènes cibles** (VCAM-1, ABCA-1, COX2, cytokines, PPARs,...)



# Conclusions

L' acide ruménique dans la matière grasse laitière est anti-athérogène (hamster hyperlipidémique)

→ importance des dépôts lipidiques (EC)



Systémique: → nonHDL-CH/HDL-CH



Local: → Efflux chol (ABCA1)



→ Recrutement des monocytes



→ inflammation







→ Détoxication des oxLDL




**Est-ce suffisant?**

**Oui et non**


Mécanisme moléculaires de la calcification artérielle (KEGG [H01002](#))






Réseau des gènes liés au sexe impliqués dans l'athérogénèse (composante sexuelle)  
Reconstitution « *in silico* » partir des données de la littérature




Diez D, Wheelock AM, Goto S, et al. The use of network analyses for elucidating mechanisms in cardiovascular disease. Mol Biosyst 2010;6:289-304.




**« conventional » so-called bottom-up strategies:  
explain complex phenotypes with only few targeted  
molecular descriptors**




Need to address the molecular basis of phenotypes  
the « top down » approach.....





# The top-down approach





<http://masspec.scripps.edu/index.php>

**Need to assess the molecular basis of phenotypes  
the « omic» answer.....**



**Contrairement au transcriptome ou au protéome, le métabolome représente l'ultime réponse d'un organisme à une altération** génétique, une pathologie, une exposition à un toxique ou à tout autre facteur susceptible de perturber son fonctionnement.

## La métabolomique (en santé) pour

la découverte de biomarqueurs et détecter l'insoupçonnable




cartographier les voies métaboliques (mécanismes, flux)


*« marché des biomarqueurs sont évalués à 694 millions de \$ en 2008, montant qui pourrait atteindre 2,2 milliards de \$ en 2015, avec des perspectives de croissance annuelle de l'ordre de 12 à 13,5 %. »*

# History


- The first paper was titled, “Quantitative Analysis of Urine Vapor and Breath by Gas-Liquid Partition Chromatography”, by Robinson and Pauling in 1971.
- Many of the bioanalytical methods used for metabolomics have been adapted (or in some cases simply adopted) from existing biochemical techniques.
- Human Metabolome project – first draft of human metabolome in 2007



# Differents Metabolomes



# Pourquoi la métabolomique est difficile?




**Plate-formes:**  
NMR  
LC/MS  
GC/MS



Sang, urines,  
extrait tissulaire

Contains latent information on:  
Genotyping, disease, Diet, Biological age



Data acquisition

MVA  
bioinformatic




Data mining






# La métabolomique: quelle infrastructure....



# Quels sont les outils de la métabolomique?

outils	avantages	défauts
RMN	Robustesse et reproductibilité	Recouvrement sensibilité
GC-MS GC X GC TOF	sensibilité	dérivation
LC-MS	sensibilité	stabilité


# Technologie & Sensibilité






# Que peut-on mesurer?

- NMR-based metabolomics (~50 metabolites identified/quantified,  $\mu\text{M}$  sensitivity)
- GC-MS based metabolomics (~70 metabolites identified/quantified,  $<\mu\text{M}$  sensitivity)
- DI-MS based metabolomics (160 metabolites identified/quantified,  $\text{nM}$  sensitivity)
- LC-MS based metabolomics (300 metabolites identified/quantified,  $\text{nM}$  sensitivity)
- Lipidomics (3000 lipids identified and semi-quantified,  $\text{nM}$  sensitivity)
- Specialty phytochemical, nutrient, drug and pesticide analysis (mostly HPLC,  $\text{nM}$  sensitivity)

intensity








**Information = 700Mo = 1 CD Rom!**





**1 variable = 1 dimension**


**1000 variables = 1000 dimensions**


**GOAL= REDUCTION WITHOUT LOSING INFORMATION**





$K$  manifest variables =  $k$  dimensional space  
(Hyperspace)














## Observations map or « score plot »









observations map :

« Score plot »



variables map :

« loading plot » ( $\cos \theta_i$ )



# Pour aller plus loin....

Metabolomics (2014) 10:361–374  
DOI 10.1007/s11306-013-0598-6

REVIEW ARTICLE

## Reflections on univariate and multivariate analysis of metabolomics data

Edoardo Saccetti · Huub C. J. Hoefsloot ·  
Age K. Smilde · Johan A. Westerhuis ·  
Margriet M. W. B. Hendriks

Environmental and Molecular Mutagenesis 54:542–557 (2013)

### Review Article

#### Deciphering the Complex: Methodological Overview of Statistical Models to Derive OMICS-Based Biomarkers

Marc Chadeau-Hyam,<sup>1,\*</sup> Gianluca Campanella,<sup>1</sup> Thibaut Jombart,<sup>2</sup> Leonardo Bottolo,<sup>3</sup> Lutzen Portengen,<sup>4</sup> Paolo Vineis,<sup>1,5</sup> Benoit Liquet,<sup>6</sup> and Roel C.H. Vermeulen<sup>4,7</sup>

# Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease

Zeneng Wang<sup>1,2</sup>, Elizabeth Klipfell<sup>1,2</sup>, Brian J. Bennett<sup>3</sup>, Robert Koeth<sup>1</sup>, Bruce S. Levison<sup>1,2</sup>, Brandon DuGar<sup>1</sup>, Ariel E. Feldstein<sup>1,2</sup>, Earl B. Britt<sup>1,2</sup>, Xiaoming Fu<sup>1,2</sup>, Yoon-Mi Chung<sup>1,2</sup>, Yuping Wu<sup>4</sup>, Phil Schauer<sup>5</sup>, Jonathan D. Smith<sup>1,6</sup>, Hooman Allayee<sup>7</sup>, W. H. Wilson Tang<sup>1,2,6</sup>, Joseph A. DiDonato<sup>1,2</sup>, Aldons J. Lusis<sup>3</sup> & Stanley L. Hazen<sup>1,2,6</sup>

7 APRIL 2011 | VOL 472 | NATURE

**50 cas avec 3 ans suivi (infarctus, AVC, mort)**  
**50 témoins**

Métabolomique LC MS plasma  
= 2000 analytes mesurés



**40 analytes fortement discriminants**

*Cohorte 1 = cohorte d'apprentissage*

*Cohorte 2 indépendante = cohorte de validation*

**50 cas avec 3 ans suivi (infarctus, AVC, mort)**

**50 témoins**

**25 cas avec 3 ans suivi (infarctus, AVC, mort)**

**25 témoins**

Métabolomique LC MS plasma  
= 2000 analytes mesurés




Métabolomique LC MS plasma  
= 2000 analytes mesurés



**40 analytes fortement discriminants**


**24 analytes fortement discriminants**



**18 analytes en commun**

**Top 3 = choline, betaine, trimethyloxyde amine (TMAO)**


## choline, betaine, trimethyloxyde amine (TMAO)= Métabolites de la phosphatidylcholine



### Validation sur modèle souris athéromateux:

- nourris avec ou sans choline
- Nourris avec ou sans TMAO
- Traités aux antibiotiques
- Cohortes humaines 1876 sujets avec angiographies


## Dosage des métabolites « athérogènes » dans une cohorte de 1876 sujets à pathologie cardiovasculaire variable (angiographie)



Implication = nouveaux marqueurs du risque cardiovasculaire, indépendant des marqueurs lipidiques classiques

Identifications de cibles thérapeutiques: flore intestinale, FMOs hépatique

### Diagnostic development process



$\alpha$ -hydroxybutyrate

X-12,063

Glycine

Phosphate

1-palmitoyl-GPE

Mannose

Hippurate

Catechol sulfate

Trigonelline

Urate

Adrenate (22:4 n6)

X-8,889

3-phenylpropionate

2-oleoyl-GPC

X-4,055

Creatine

Decanoyl-carnitine

X-11,793

Eicosenoate (20:1 n9 or 11)

Cysteine

Glutamate

Octanoyl-carnitine

Isoleucine

X-11,421

Linoleoyl-LPC

X-13,431

X-7,888


X-11,537

$\alpha$ -ketobutyrate

1-oleoyl-GPC

	Predicted		
	Actual	> 45 M <sub>FFM</sub>	$\leq 45 M_{FFM}$
> 45 M <sub>FFM</sub>	201	60	
$\leq 45 M_{FFM}$	36	102	
% correct		76%	


Mean decrease accuracy



**Table 1 Biomarker candidates**

2-hydroxybutyrate	Linoleic acid	Stearate
3-hydroxybutyrate	Linolenic acid	Threonine
3-methyl-2-oxo-butyric acid	Margaric acid	Isovalerylcarnitine
3-phenylpropionate	Octanoyl carnitine	Linoleoyl-LPC
Catechol sulfate	Oleic acid	1,5-anhydroglucitol
Creatine	Oleoyl-LPC	Stearoyl-LPC
Decanoyl carnitine	Palmitate	1-palmitoyl-GPE
Docosatetraenoic acid	Palmitoleic acid	Octanoylcarnitine
Glutamic acid	Palmitoyl-LPC	$\alpha$ -ketobutyrate
Glycine	Serine	Cysteine


# Couplage avec autres omiques




## **Statistically Integrated Metabonomic–Proteomic Studies on a Human Prostate Cancer Xenograft Model in Mice**

Mattias Rantalainen,<sup>†</sup> Olivier Cloarec,<sup>†</sup> Olaf Beckonert,<sup>†,‡,§</sup> I. D. Wilson,<sup>‡</sup> David Jackson,<sup>§</sup> Robert Tonge,<sup>§</sup> Rachel Rowlinson,<sup>§</sup> Steve Rayner,<sup>§</sup> Janice Nickson,<sup>§</sup> Robert W. Wilkinson,<sup>||</sup> Jonathan D. Mills,<sup>||</sup> Johan Trygg,<sup>\*,†</sup> Jeremy K. Nicholson,<sup>†</sup> and Elaine Holmes<sup>\*,†</sup>

Multiple correlations between metabolites and proteins were found, including associations between serotransferrin precursor and both tyrosine and 3-D-hydroxybutyrate. Additionally, a correlation between decreased concentration of tyrosine and increased presence of gelsolin was also observed. This approach can provide enhanced recovery of combination candidate biomarkers across multi-omic platforms, thus, enhancing understanding of in vivo model systems studied by multiple omic technologies



# Subnetwork of strongly interacting pathways to metabolites clusters




# Proteasome Subunits mRNA Expressions Correlate With Male BMI: Implications for a Role in Obesity

Obesity (2009) **17**, 1044–1049.

# Adipose Tissue IL-6 Content Correlates with Resistance to Insulin Activation of Glucose Uptake both *in Vivo* and *in Vitro*

The Journal of Clinical Endocrinology & Metabolism 87(5):2084–2089



EGFR Tyrosine Kinase Inhibitor (PD153035) Improves Glucose Tolerance and Insulin Action in High-Fat Diet–Fed Mice

DIABETES, VOL. 58, DECEMBER 2009



Site-dependent differences in both prelamin A and adipogenic genes in subcutaneous adipose tissue of patients with type 2 familial partial lipodystrophy

J Med Genet 2009; **46**:40–48.

Conjugated Linoleic Acid Supplementation Reduces Adipose Tissue by Apoptosis and Develops Lipodystrophy in Mice


DIABETES, VOL. 49, SEPTEMBER 2000

Major impact of CLA on adipocytes




## Integrative Biological Analysis of the APOE\*3-Leiden Transgenic Mouse


CLARY B. CLISH,<sup>1</sup> EUGENE DAVIDOV,<sup>1</sup> MATEJ ORESIC,<sup>1</sup>  
THOMAS N. PLASTERER,<sup>1</sup> GARY LAVINE,<sup>1</sup> TOM LONDO,<sup>1</sup> MICHAEL MEYS,<sup>1</sup>  
PHILIP SNELL,<sup>1</sup> WAYNE STOCHAJ,<sup>1</sup> ARAM ADOURIAN,<sup>1</sup> XIANG ZHANG,<sup>1</sup>  
NICOLE MOREL,<sup>1</sup> ERIC NEUMANN,<sup>1</sup> ELWIN VERHEIJ,<sup>2</sup> JACK T.W.E. VOGELS,<sup>2</sup>  
LOUIS M. HAVEKES,<sup>3,4</sup> NOUBAR AFEYAN,<sup>1</sup> FRED REGNIER,<sup>5</sup>  
JAN VAN DER GREEF,<sup>1,2,6</sup> and STEPHEN NAYLOR<sup>1</sup>



## Evaluer l'impact athérogénique de différentes matières grasses laitières anhydres +/-décholestérolisées et appauvries en AGS



## Régimes tests



Metabolome plasmatique n=701 (LCMS)

Metabolome urines n=1224 (LCMS)

Chimie du sang =26 (biochimie: TG, Chol,  
HDLC, LDLC,...)

Acides gras foie & classes lipidiques du plasma  
n=124 (fast-GC)


Expression gènes foie et sang n=44 (QPCR)

**Total = 1666 variables biologiques/hamster + 1 (mesure indice athérogénicité)**



## But

- identifier des biomarqueurs prédictifs de l'athérogénèse sensibles aux régimes;




Lésions peu étendues

Lésions étendues



Marqueurs biologiques des lésions ( $f(\text{régimes})$ )?

1666 variables biologiques/hamster



*Sélection selon critère VIP de  
l'analyse discriminante  
multivariée PLS*

127 variables biologiques discriminantes



38 métabolome  
urine



38 métabolome  
plasma



23 acides gras  
(PL, CE, TG,  
Lipides totaux)



12 biochimie  
sang



16 gènes

## AA metabolism


## Regulation of lipid transport and metabolism

## Vit E metabolism

## Mitochondrion function


# Dairy fat derived fatty acids

# **hemostasis**






### Biological clusters

Blood cholesterol related  
 Endogenous derived fatty acids  
 dairy fat derived fatty acids  
**Regul. of lipid metab. & transp.**  
 mitochondrion function  
 miscellaneous & unidentified  
 inflammation  
 hemostasis  
 Aminoacids metabolism  
 Vitamin E metabolism



**Predicted Atherogenicity** = 0.108091\*[dairy fat derived fatty acids] + 0.152669\*[endogenous derived fatty acids] - 0.0340185\*[mitochondrion function] + 0.173429\*[regul. Lipid metab. Trans.] - 0.0751566\*[vitaminE metabolism] - 0.153142\*[hemostasis] - 0.110269\*[aminoacids metabolism] + 0.110269\*[blood cholesterol related] + 0.231903\*[inflammation] - 0.00456344\*[miscellaneous & unidentified] + **4.06731**.






# Quelques applications en sélection cultivars, origine produits, qualité

**Table 1.** A selection of metabolomic studies on common foods summarizing the purpose of these studies, the methodologies used and the major conclusions reached

Purpose	Plant/food	Sample preparation	Analysis	Data analysis	Outcome	Reference
Metabolite diversity/ breeding	Raspberries	Acetic acid/acetonitrile	DIMS-LC-MS	PCA	Variation attributed to anthocyanins	Stewart et al. [26]
Metabolite diversity/ breeding	Tomatoes	MeOH with H <sub>2</sub> O/ chloroform partition	GC-MS	PCA	Identification of 889 metabolic loci, metabolites associated with yield trait	Schauer et al. [24]
Metabolite diversity/ breeding	Potatoes	MeOH with H <sub>2</sub> O/ chloroform partition	GC-MS	PCA Correlation	Detected variation between cultivars and landraces	Dobson et al. [27, 28]
Geographic origin	Grapes/wine	95% EtOH	NMR	PCA/PLS-DA	Grapes from different regions can be distinguished	Son et al. [69]
Geographic origin	Coffee	MeOH/H <sub>2</sub> O	GC-FID/LCMS	PCA	Samples from Asia, Africa, and S. America could be distinguished	Choi et al [35]
Geographic origin	Green tea	Hot H <sub>2</sub> O	NMR	PCA/OPLS-DA	Growing region with high temperature, rainfall and sun increased theanine concentrations	Lee et al. [70]
Geographic origin	Olive oil	SPME	GC-MS	Linear discriminant analysis	Distinguished from different production areas within a region	Cavaliere et al. [36]
Quality	Green tea	MeOH/H <sub>2</sub> O/chloroform	GC-MS/LC-MS	PCA/OPLS-DA	Tea grown on greater shade had higher umami and less astringency and these attributes were related to sugars, amino acid and phenolics	Ku et al. [71]
Postharvest disorder	Apples		GC-MS			Rudell et al. [38]
Sensory	Tomatoes	Lyophilisation/SPME/ extraction H <sub>2</sub> O:MeOH	GC-MS and LC-MS	PCA/PLS (with validation)		Thissen et al. [21]
Sensory	Wine/grapes	Wine directly added to NMR tubes	NMR	PCA/PLS-DA	Metabolites related to sun/shade treatments and mouth-feel parameters	Rochfort et al. [39]
GM assessment	Tomatoes	80% MeOH/H <sub>2</sub> O	GC-MS, LC-MS, CE-MS	ANOVA/PCA	GM lines were within traditional cultivar variation	Kusano et al. [41]

Characterization and classification of Western Greek olive oils according to cultivar and geographical origin based on volatile compounds

Eirini Pouliarekou<sup>a</sup>, Anastasia Badeka<sup>a</sup>, Maria Tasioula-Margari<sup>a</sup>, Stavros Kontakos<sup>b</sup>, Francesco Longobardi<sup>c</sup>, Michael G. Kontominas<sup>a,\*</sup>




**Fig. 3.** Classification of olive oil samples from Western Greece according to cultivar using (a) 53 variables and (b) 19 variables.

# Metabolomics and molecular marker analysis to explore pepper (*Capsicum* sp.) biodiversity


Yuni Wahyuni · Ana-Rosa Ballester · Yury Tikunov ·  
Ric C. H. de Vos · Koen T. B. Pelgrom · Awang Maharijaya ·  
Enny Sudarmonowati · Raoul J. Bino · Arnaud G. Bovy

Metabolomics (2013) 9:130–144



# Metabolite profiling of maize grain: differentiation due to genetics and environment

Richard M. Röhlig · Joachim Eder ·  
Karl-Heinz Engel



# Apple Peels, from Seven Cultivars, Have Lipase-Inhibitory Activity and Contain Numerous Ursenoic Acids As Identified by LC-ESI-QTOF-HRMS

micrOTOF QII mass spectrometer

Tony K. McGhie,\* Sébastien Hudault, Rona C. M. Lunken, and John T. Christeller

Table 3. Relative Amount of Each Compound Measured Normalized to Total Peak Area

no.	compound name	average	'Braeburn'	'Granny Smith'	'Sciros'	O.P. 'Red Field'	'Cripps Pink'	'Fuji'	'Scilate'
1	dihydroxy-urs-12-en-28-oic acid	0.13	0.14	0.00	0.22	0.24	0.07	0.12	0.07
2	unknown	1.64	1.37	0.13	0.53	1.24	6.39	0.73	0.59
3	unknown	0.76	0.44	1.21	0.48	2.14	0.53	0.26	0.26
4	unknown	1.76	1.04	1.60	1.77	4.65	1.26	0.73	1.01
5	trihydroxy-urs-12-en-28-oic acid	2.48	2.03	1.88	0.63	0.49	4.10	3.16	5.34
6	trihydroxy-urs-12-en-28-oic acid	0.11	0.28	0.01	0.26	0.24	0.00	0.00	0.00
7	unknown	2.50	1.00	1.91	3.63	6.64	0.75	0.77	2.49
8	unknown	3.45	2.75	2.56	3.07	5.14	4.18	3.34	2.56
9	tetrahydroxy-urs-12-en-28-oic acid	1.26	5.28	0.08	1.16	1.68	0.38	0.20	0.23
10	unknown	0.93	1.25	0.88	0.35	1.84	0.74	0.78	0.64
11	3-oxo-1,19 $\alpha$ -dihydroxy-urs-12-en-28-oic acid (anursenoic acid)	8.39	12.32	5.08	9.27	8.90	8.79	6.40	7.80
12	unknown	3.35	5.22	3.35	1.02	5.69	2.77	3.35	2.04
13	unknown	2.25	3.44	2.33	1.34	3.30	1.49	2.29	1.62
14	3-oxo-1 $\alpha$ -hydroxy-urs-12-en-28-oic acid	2.14	4.91	1.25	2.02	1.98	2.21	1.21	1.55
15	$\beta$ -p-coumaroyloxy-dihydroxy-urs-12-en-28-oic acid	1.54	1.53	0.17	0.23	0.51	1.70	2.60	4.01
16	$\beta$ , $\beta$ ,19 $\alpha$ -dihydroxy-urs-12-en-28-oic acid (pomoic acid)	1.86	1.73	1.66	1.96	1.78	1.69	1.62	2.65
17	3-oxo-hydroxy-urs-12-en-28-oic acid	3.69	5.38	4.98	5.45	2.74	2.58	2.21	3.20
18	total ursenoic acids peak area	3,630,859	3,110,778	4,243,395	4,381,954	4,207,580	4,753,673	3,507,671	
total ursenoic acids peak area		39	71	60	64	70	60	50	
% lipase inhibition									
27	unknown	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
28	oxo-urs-12-en-28-oic acid	0.59	0.90	0.61	0.81	0.51	0.37	0.49	0.51
29	unknown (dihydroxy-urs-12-en-28-oic acid)	1.91	3.13	1.73	2.38	1.86	1.39	1.59	1.35
30	oxo-urs-12-en-28-oic acid	1.96	3.21	2.04	3.39	1.33	1.16	1.29	1.49
31	3-oxo-hydroxy-urs-12-en-28-oic acid	2.56	8.63	0.00	0.00	2.21	2.01	3.28	1.79
32	3-oxo-hydroxy-urs-12-en-28-oic acid	2.04	0.00	1.93	2.97	2.57	1.94	2.15	2.42
33	$\beta$ -, $\beta$ -p-coumaroyloxy-hydroxy-urs-12-en-28-oic acid	2.00	1.08	1.94	2.83	1.21	1.49	2.94	2.31
34	$\beta$ -trans-p-coumaroyloxy-2 $\alpha$ -hydroxy-urs-12-en-28-oic acid	6.34	3.67	4.94	8.94	4.18	5.29	8.95	7.65
35	$\beta$ -cis-p-coumaroyloxy-2 $\alpha$ -hydroxy-urs-12-en-28-oic acid	4.35	1.33	7.18	5.76	2.32	3.55	6.05	4.46
36	oxo-urs-12-en-28-oic acid	2.83	3.39	4.29	4.20	2.25	1.63	2.06	2.50
37	$\beta$ -hydroxy-lup-20(29)-en-28-oic acid (betulinic acid)	6.03	3.80	9.62	5.85	4.92	6.76	5.33	6.85
38	$\beta$ -hydroxy-urs-12-en-28-oic acid (ursolic acid)	5.41	4.48	8.56	5.36	3.95	5.56	4.55	6.45
39	unknown	1.29	0.31	0.00	0.07	4.40	2.65	0.12	1.00
40	unknown	2.26	1.05	3.74	1.90	1.79	2.63	2.26	2.80
41	unknown	6.49	3.78	9.76	6.10	5.40	7.19	6.12	7.85
42	$\beta$ -hydroxy-urs-12-en-28-ol (uvaol)	5.06	1.53	6.42	2.53	3.23	5.70	11.70	3.12
43	unknown	1.70	0.86	1.39	1.36	1.25	2.40	1.97	2.60
total ursenoic acids peak area		3,630,859	3,110,778	4,243,395	4,381,954	4,207,580	4,753,673	3,507,671	
% lipase inhibition		39	71	60	64	70	60	50	



# Metabolomics-Driven Nutraceutical Evaluation of Diverse Green Tea Cultivars

Yoshinori Fujimura<sup>1,9</sup>, Kana Kurihara<sup>2,9</sup>, Megumi Ida<sup>2</sup>, Reia Kosaka<sup>2</sup>, Daisuke Miura<sup>1</sup>, Hiroyuki Wariishi<sup>1,2,3</sup>, Mari Maeda-Yamamoto<sup>4</sup>, Atsushi Nesumi<sup>4</sup>, Takeshi Saito<sup>5</sup>, Tomomasa Kanda<sup>5</sup>, Koji Yamada<sup>2</sup>, Hirofumi Tachibana<sup>1,2,3\*</sup>

Analyse métabolomique de différents cultivars de thé vert

Test biologique (dysfonction vasculaire *in vitro*) des différents cultivars de thé vert

Cultivars biologiquement actifs/non actifs

Métabolites discriminants des cultivars

Métabolites associés à l'activité biologique


Cultivars possédant les métabolites actifs



Validation = transfert de l'activité biologique par ajout des métabolites suspectés actifs à un cultivar initialement inactif (ex: importance bio THEANIN)

# Decoding genes with coexpression networks and metabolomics – ‘majority report by precogs’

TRENDS in Plant Science Vol.13 No.1

Kazuki Saito<sup>1,2</sup>, Masami Y. Hirai<sup>1</sup> and Keiko Yonekura-Sakakibara<sup>1</sup>






Co-expression de gènes associés à l'assimilation du soufre avec O-acetylsérine

Fonction de gènes inconnus


coaccumulated metabolites. A set of genes involved in the same metabolic pathway and thus coordinately regulated under the sulfur-starved condition were found as a cluster [e.g. genes of glucosinolate biosynthesis, genes and a metabolite (*O*-acetylserine) of the sulfur assimilation pathway and genes of anthocyanin biosynthesis]. These clusters contained novel genes for enzymes and transcription factors to be further characterized [17,20]. *O*-Acetylserine, an intermediary and regulatory metabolite of the sulfur assimilation pathway, was found in the same cluster as the genes of this pathway [17].

# CRIBIOM, une plate-forme de criblage biologique



# Projet « Polygone »


Onidol, PIVERT, U-Caen, AMU  
GENESYS/SAS PIVERT



## « omiques »

# CRIBIOM

## Métabolomique et lipidomique



LC QTOF



GCMS



LC orbitrap



fastGCFID

## Transcriptomique



Plate forme microarray (IFR)



QPCR

## Plate-formes expérimentales




animalerie



Cultures cellulaires

## Bioinformatique, statistiques et modélisation in silico



# Quels sont les éléments qui fragilisent encore le développement de la métabolomique?






**Reproductibilité inter-plateforme et standardisation**



MS instruments (TOF, QTOFs, orbitrap)



NMR instruments




*Despite a large differences in the number of features among the instruments, the heterogeneity in the analytic conditions and data post-processing, the spectral information within (NMR and MS) and across methods (NMR vs MS) was highly converging (from 64% to 91% on average). No effect of the MS configuration (TOF, QTOF, Orbitrap) was noticed*



**Facteurs humains: scepticisme et conservatisme des biologistes, formation insuffisante**

*Les progrès à attendre*





De la métabolomique à l'intégration omique




## Spectro de masse




## Banque de données



## Identifier et annoter







## A New Biology for the 21st Century

Committee on a New Biology for the 21st Century:  
Ensuring the United States Leads the Coming Biology  
Revolution; National Research Council

ISBN: 0-309-14489-2, 112 pages, 6 x 9, (2009)

**This free PDF was downloaded from:**

<http://www.nap.edu/catalog/12764.html>

